A drug called Coversin is being investigated as a potential treatment for four orphan diseases: bullous pemphigoid (BP), atypical keratoconjunctivitis (AKC), thrombotic microangiopathies, and paroxysmal nocturnal hemoglobinuria (PNH). Recently, new information has been released about the effects of Coversin in two paediatric patients with thrombotic microangiopathies (TMA). For more information about this, you can view the source press release here, at Globe Newswire.
Coversin is a combined complement C5 and leukotriene B4 inhibitor that Akari Therapeutics is developing as a potential treatment for four orphan conditions. Currently, a Phase II study of the drug in patients with BP is recruiting patients, and the first data is expected to be released early next year. There is also an on-going Phase I/II study of Coversin in patients with AKC, and an on-going Phase 3 study of the drug in patients with PNH. Following the collection of data from two patients who took Coversin for TMA, Akari says that it plans to carry out a formal clinical trial investigating the drug for this use.
About Thrombotic Microangiopathies (TMA)
TMA is a form of damage that affects the smallest blood vessels in organs, and often in the kidney or brain. When these vessels are damaged, it can slow the flow of blood and injure substances in the blood, such as red blood cells and platelets. When blood stops flowing to a part of the body, that area can become damaged and may die. TMA is a very serious medical condition, however, developments in medicine have improved the prognoses for patients who develop it. This information is from the UNC School of Medicine, and you can read more about TMA by clicking here.
New Data on Patients with TMA Treated with Coversin
Two paediatric patients were treated with Coversin after showing signs of post-transplant TMA. After being given Coversin, the symptoms of both patients resolved. Akari has said that, following this data, they plan to research Coversin for TMA in a clinical trial.